In a highlight from the second annual "CPhI 2014 Expert Industry Annual Report: Part I," Vijay Shah of Piramal Enterprises discusses the benefits of adopting greener practices.
CPhI Worldwide released the first part of its second annual report, which included Vijay Shah, Executive Director, COO, and expert in green technologies at Piramal Enterprises, a global pharmaceutical company specializing in inhalation anesthesia and custom manufacturing. Shah commented that to reduce costs, increase efficiency, and lower environmental impact, organizations must include green chemistry as part of their business strategy.
"In the future, green chemistry methodologies will be ingrained into the R&D stage. Green Chemistry by Design (GCbD) will be taken up by the leading CRAMs (Contract Research and Manufacturing Services) industry players to help drive efficiency savings,” said Vijay Shah, in the report highlights.
Shah also explained that adopting green chemistry might save $65 billion, which would improve the overall return on investment for the industry. As an incentive for companies to begin to adopt these strategies, Shah reasoned that the government must step in and revise regulations to make it easier for companies to adopt green strategies, while offering government incentives for meeting specific goals. If companies are offered incentives, it may prioritize movements toward greener practices.
CPhI will release the full report with additional expert articles at CPhI Worldwide 2014 in Paris Nord Villepinte, France.
Source: CPhI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.